More Business Wire
View Older Stories View Newer Stories-
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Ouster, Inc. Announces Pricing of Public Offering of Common Stock
-
CleanAmps and Excelsior Energy Capital Expand Strategic Collaboration to Accelerate Deployment of U.S.-Owned Digital Infrastructure Platform
-
United Therapeutics Corporation Acquires Thymmune Therapeutics
-
Ingevity announces dates for second quarter 2026 earnings release and webcast
-
Infobip Launches PitchMate — An AI Fan Companion for Global Football
-
KBRA Assigns Preliminary Ratings to Morglas ABS 2026-1 PLC
-
M6 Metropole Television: Separation of the “Stéphane Plaza Immobilier” and “Sixieme Avenue, l'immobilier par M6” Networks
-
Besins Healthcare Strengthens Innovation Capabilities with Acquisition of UniD Manufacturing, a Specialist in Long-Acting Drug Delivery Technologies
-
ROYC Selected by Slättö as Structuring and Platform Solution for Luxembourg Feeder Fund
-
SkyDrive Marks a Total of 300 Flights without Incident
-
RGREEN INVEST Partners with Arverne Founder and CEO Pierre Brossollet Through GEOGREEN to Advance Geothermal Energy and Strengthen Europe's Energy Security
-
Teledyne Promotes Michelle Hildyard to General Manager of Teledyne Raymarine and Teledyne FLIR Marine
-
Barclays, HSBC, Lloyds, and NatWest among the first banks in the world to adopt new Swift framework for enhanced international consumer payments
-
Sopra Steria Elevates Service Center Performance with NiCE, Advancing AI-Driven Operational Excellence Across Europe
-
World Cup Kick-Off Times Rewrite Hospitality Trading Patterns, Fourth Analysis Reveals
-
From SaaS to OaaS: BearingPoint expands its business model and launches outcome-based marketplace
-
Malaysia: TotalEnergies Divests its Minority Non-Operated Interest in Marjoram Gas Field
-
EVE Energy Strengthens European Operations Through Compliance, Local Manufacturing, and Regional Services
-
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
-
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
-
Metapack® Named OneStock's Strategic Delivery Management Partner
-
Braun Launches the Next Generation of Electric Shaver With Braun NEVO Introducing a New Dawn of Smooth Touch
-
Nebius celebrates healthcare and life sciences innovators at expanded AI Discovery Awards
-
CoStar Group Announces Launch of CoStar Platform in France
-
Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member
-
Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer
-
Mitsubishi Electric Wholly Acquires Infostellar to Expand Ground Station Services for Satellite Operators
-
NTT Global Data Centers Report Reveals What It Will Take to Power the Next Wave of AI
-
CaratIQ Announces Exclusive Partnership with Nationwide Jewellers to Bring AI-Powered Cloud POS Technology to Australia and New Zealand
-
IMS Group to Appoint John M. Caccia as Chairman and Partner
-
Forgent Power Solutions Announces Pricing of Upsized Public Offering of Class A Common Stock
-
Final State Budget Brings $5M for New Behavioral Health Pilot to Central Coast
-
8x8 Named 2026 MetriStar Top Provider for CPaaS by Metrigy, Recognised Across Three Categories
-
The AI Winners Won’t Just Be The Most Technological. They’ll Be The Most Human.
-
Civeo Awarded Six-Year Western Canada Contract Renewal
-
Civeo Corporation Prices $100.0 Million Convertible Senior Notes Offering
-
Access Advance and Alibaba Announce Alibaba's Expanded Participation in the VDP Pool
-
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
-
BBHW Supports DEA Scheduling of 7-OH and Three Related Drugs is an Important Step to Take Dangerous, Synthetic Products Off of the Market
-
Faraday Future Showcases its EAI Robotics Education Ecosystem at ISTE Live 2026 in Orlando, Drawing Strong Interest from Major North American Education Distributors and Procurement Leaders
-
Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney Function in IgA Nephropathy (Ig
-
UFC Delivers Knockout Results for Sydney
-
NHC Completes Acquisition of Thirty-Five NHI Facilities
-
Solid Power Appoints Uwe Breitweg to Board of Directors, Adding Deep Automotive and Battery Strategy Expertise
-
Bayer Group to Consolidate U.S. Glyphosate Business Into Distinct Entity Operating as Ruveon
-
Ruveon Launches as Dedicated U.S. Glyphosate Leader
-
NorthWestern Energy to Host Second Quarter 2026 Financial Results Webinar
-
VIVAZEN® Commends the Drug Enforcement Administration’s Decision to Schedule Synthetic 7-Hydroxymitragynine (7-OH) and Three Related Drugs
-
Kilroy Realty Corporation Announces Dates for Second Quarter 2026 Earnings Release and Conference Call
